By Katherine Dillinger, CNN (CNN) — A three-year study of tirzepatide – a medication approved in the US as Zepbound for diabetes and Mounjaro for weight loss – found that when adults who had prediabetes and obesity or overweight used it weekly, it lowered their risk of progression to diabetes by 94% compared with a placebo, according to drugmaker Eli Lilly. The company said Tuesday that people who got a 15-milligram (mg) dose of the medicine also had an average decrease in body weight of nearly 23%, compared with 2.1% in those who got a placebo. During a 17-week off-treatment follow-up period, people who had stopped using tirzepatide began to regain weight, Lilly said in a news releas
Hence then, the article about tirzepatide cuts risk of diabetes by 94 in adults with prediabetes and obesity or overweight drugmaker says was published today ( ) and is available onNews channel ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Tirzepatide cuts risk of diabetes by 94% in adults with prediabetes and obesity or overweight, drugmaker says )